BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
NASA astronauts to return from space early due to an 'unexpected medical issue.' What happened — and when are they coming home? - 2Intriguing Strange Cruising Objections you Should Visit
- 3What's Your Number one Superhuman Film Made?
- 4France will build a new aircraft carrier as it increases defense spending
- 5Best Augmented Simulation Ride: Which One Feels Generally Genuine?
- Sports Shoes of 2024: Upgrade Execution and Solace
- Europe picks companies to help build Argonaut moon lander
- A Concise History Of The Entertainment world
- What’s your chronotype? Knowing whether you’re a night owl or an early bird could help you do better on tests and avoid scams
- ‘It’s Israeli policy’: Report reveals abuse of Palestinians in prisons
- Bolsonaro briefly leaves Brazilian prison for medical tests after a fall from his bed
- Revvity says it will exceed 2025 profit forecast range
- How does Spotify Wrapped calculate your listening age? What your number says about you.
- A new mom skipped a routine appointment. An infected cut led to a devastating diagnosis
